FDA Public Education On ED Drug Vision Risk Is Lacking, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Finance Committee chair seeks FDA strategy for disseminating drug safety information to patients not requiring physician follow-up.
You may also be interested in...
Public Citizen Urges “Black Box” On Vision Loss For Erectile Dysfunction Drugs
The advocacy group’s petition also asks FDA to require that manufacturers establish a patient registry to track cases of non-arteritic ischemic optic neuropathy.
Public Citizen Urges “Black Box” On Vision Loss For Erectile Dysfunction Drugs
The advocacy group’s petition also asks FDA to require that manufacturers establish a patient registry to track cases of non-arteritic ischemic optic neuropathy.
Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss
Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”